Gian Lifecare (542918)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value of ₹21.38 provides a tangible asset anchor; P/B of 1.07 means the price is not far above stated book value.
• ROCE is positive at 2.40%, indicating some return from capital employed despite weak profitability.
• Price close to book value may limit downside if the reported assets are genuine and conservatively valued.
• As a listed healthcare service provider, it operates in a sector with potential long-term demand tailwinds.

Concerns

• Sales growth is -29.56% and profit growth is -71.43%; latest quarterly net profit is ₹0 Cr.
• ROE is negative at -3.84% and Piotroski F-Score is 3/9, signaling weak financial health.
• No dividend and P/E of 0.00 mean there is no income or earnings support for the valuation.
• Promoter holding data is N/A, so ownership and governance transparency cannot be assessed.

AI Analysis

At ₹22.89, Gian Lifecare has a market capitalization of just ₹24 crore. The book value per share is ₹21.38, so the stock trades at 1.07 times book. That seems close to a Graham-style asset situation. But the business underneath is weak. Sales have fallen by 29.56%, profit has fallen by 71.43%, and the latest quarter shows revenue of only ₹1 crore with net profit of zero. A negative return on equity of -3.84% means the company is not earning its cost of equity. Return on capital employed is a meager 2.40%, far below what I would expect from a healthcare service provider with a durable advantage. The P/E ratio is meaningless because there are no real earnings to speak of. I also see no dividend, so the shareholder has no return while waiting. The Piotroski F-Score of 3 out of 9 reinforces my concern: the financial health is poor. This stock has gone from ₹5.43 to ₹22.89, at the top of its 52-week range, yet the operating numbers show deterioration, not improvement. I cannot identify a moat, pricing power, or evidence of smart capital allocation. The only potential support is the stated book value, but book value is only useful if the assets can generate future earnings or be realized. With shrinking sales and no profit, the margin of safety is too thin. As Benjamin Graham would say, price is what you pay, value is what you get. I see a small, unprofitable business trading at a premium to book, not an undervalued franchise. This is, at best, an asset play, and only worth investigating further if the balance sheet is conservative and operations stabilize. Until then, I would rather wait for a better price or clearer evidence of a turnaround.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer